Lexicon Shares Jump 20 Percent Following Positive Results From Mid-Stage Diabetic Neuropathy Study

Lexicon Pharmaceuticals LXRX reported positive topline results from the Phase 2 proof-of-concept study of its lead candidate LX9211 in painful diabetic neuropathy.

The RELIEF-DPN-1 is the first of two Phase 2 proof-of-concept study designed to evaluate LX9211 in patients with neuropathic pain.

In this study, LX9211 has achieved the primary endpoint, demonstrating a statistically significant reduction in average daily pain score (ADPS) at week 6 compared to placebo in the low dose arm with results that plateaued in the high dose arm. 

Craig Granowitz, Senior vice president and chief medical officer, commented : “The results of this study support the translation of a potential new mechanism of action for neuropathic pain and serve as a testament to the strength of Lexicon's science. Our scientists were the first to identify AAK1 as a novel target with potential for the treatment of neuropathic pain, making an initial discovery in knockout mice, validating that discovery in collaboration with Bristol-Myers Squibb with small molecule inhibition of the target in animal models, and now translating that discovery in this human clinical proof-of-concept study. “

LX9211 is also under evaluation in RELIEF-PHN-1, the second Phase 2 study in patients with post-herpetic neuralgia. Lexicon expects top-line results around the end of the third quarter of 2022.

The company noted that complete analysis of the results from RELIEF-DPN-1 will be submitted for publication at an upcoming medical conference and in a peer-reviewed journal.

Lexicon shares are trading higher 20 percent at $2.68 during after hours session on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechPenny StocksHealth CareMovers & ShakersSmall CapGeneralBiotechnologyHealth CareTopline Results
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!